RT Journal Article
SR Electronic
T1 Selective Inhibitors of Cyclooxygenase-2 Delay the Activation of Nuclear Factor κB and Attenuate the Expression of Inflammatory Genes in Murine Macrophages Treated with Lipopolysaccharide
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 671
OP 677
DO 10.1124/mol.63.3.671
VO 63
IS 3
A1 Callejas, Nuria A.
A1 Fernández-Martı́nez, Amalia
A1 Castrillo, Antonio
A1 Boscá, Lisardo
A1 Martı́n-Sanz, Paloma
YR 2003
UL http://molpharm.aspetjournals.org/content/63/3/671.abstract
AB The effect of rofecoxib, a selective cyclooxygenase-2 inhibitor, on inflammatory signaling has been investigated in elicited murine peritoneal macrophages. Macrophages treated with 10 μM rofecoxib exhibited an important inhibition in the early activation of nuclear factor κB (NF-κB) and the mitogen-activated protein kinase p38, the extracellular-regulated kinase p44, and the c-Jun N-terminal kinase. Moreover, this drug decreased the protein levels of nitric-oxide synthase-2 and cyclooxygenase-2 in lipopolysaccharide (LPS)-treated macrophages. Rofecoxib delayed and attenuated NF-κB activation, which impaired significantly the expression of κB-dependent genes. This drug and related coxibs did not affect cell viability and protected against LPS-induced apoptosis through the impairment of the inflammatory response. These data show an additional anti-inflammatory mechanism of selective cyclooxygenase-2 inhibitors through the attenuation of macrophage activation.